Results 91 to 100 of about 11,700 (225)

Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics [PDF]

, 2016
INTRODUCTION: To investigate the efficacy of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery. METHODS: Single arm, prospective, interventional multicenter study.
Biagioli, Elena, Galli, Francesca, Hollander, Lital, Katsanos, Andreas, Longo, Antonio, Poli, Davide, Quaranta, Luciano, Riva, Ivano, Rulli, Eliana, Torri, Valter, Uva, Maurizio G., Weinreb, Robert N.   +11 more
core   +2 more sources

Nuevos Tratamientos para el Glaucoma: Inhibidores de Rho-quinasa [PDF]

, 2019
En la presente revisión bibliográfica hemos recogido información acerca de los inhibidores de Rho-quinasa como nuevos fármacos para el tratamiento del glaucoma primario de ángulo abierto.
Ruiz Sánchez, Cristina
core  

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination

Clinical Ophthalmology, 2020
Kenji Inoue,1 Hua Piao,1 Mayumi Iwasa,1 Kyoko Ishida,2 Goji Tomita2 1Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, JapanCorrespondence: Kenji InoueInouye Eye Hospital, Chiyoda-ku, Tokyo ...
Inoue K, Piao H, Iwasa M, Ishida K, Tomita G   +4 more
doaj  

Effects of latanoprost in iris bioidentification [PDF]

, 2009
Heikki Lamminen, Ville Voipio, Tapio Manninen, Heikki Huttunen   +3 more
openalex   +1 more source

Latanoprost in the treatment of glaucoma

Clinical Ophthalmology, 2014
Albert AlmDepartment of Neuroscience, Ophthalmology, University Hospital, Uppsala, SwedenAbstract: Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma.
Alm A
doaj  

A Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Latanoprost 0.005% and Timolol 0.5% Dosed Concomitantly in Patients with Open-Angle Glaucoma or Ocular Hypertension [PDF]

, 2011
Background/Aims: To compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% in fixed combination with the unfixed combination of latanoprost 0.005% and timolol 0.5% in open-angle glaucoma or ocular hypertension patients
Bergamini, Michael VW, Landry, Theresa A, Mallick, Sushanta, Peace, James H, Rhee, Douglas J, Study Group   +5 more
core  

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival [PDF]

, 2022
Josefine Freiberg, Anne Hedengran, Steffen Heegaard, Goran Petrovski, Jette Bredahl Jacobsen, Barbara Cvenkel, Miriam Kolko   +6 more
openalex   +1 more source

The Efficacy of Latanoprost in the Treatment of Alopecia Areata of Eyelashes and Eyebrows

مجله دانشکده پزشکی اصفهان, 2012
Background: Latanoprost is an analogue of prostaglandin F2a which is used to treat glaucoma. Increases in eyelash number, thickness, and pigmentation have been reported as latanoprost side effects.
Gita Faghihi, Fatemeh Andalib, Ali Asilian   +2 more
doaj  

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

Clinical Ophthalmology, 2020
Nathan Radcliffe,1 John Berdahl,2 Mitchel Ibach,2 Justin Schweitzer,2 Jason Levine,3 Sean McCafferty3 1New York Eye Surgery Center, New York, NY, USA; 2Vance Thompson Vision, Sioux Falls, SD, USA; 3Arizona Eye Consultants, Tucson, AZ, USACorrespondence ...
Radcliffe N, Berdahl J, Ibach M, Schweitzer J, Levine J, McCafferty S   +5 more
doaj  

Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects

Clinical Ophthalmology, 2010
Robert D Steigerwalt Jr1, Gianni Belcaro1, Paolo Morazzoni2, Ezio Bombardelli2, Carolina Burki3, Frank Schönlau4 1Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy; 2Indena S.p.A. Scientific Department, Milan,
Robert D Steigerwalt Jr, Gianni Belcaro, Paolo Morazzoni, et al   +3 more
doaj